- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Endometrial cancer
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 703KB)
Dostarlimab – November 2023
Dostarlimab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Jemperli®
Last updated
1 March 2024